Malaysian Genomics Sealed Collaboration with NIH on Research in Genomics and Biopharmaceuticals

MGRC Therapeutics (MGRC-T), the wholly-owned subsidiary of Malaysian Genomics, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals.

The National Institutes of Health (NIH) which is the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies.

The NIH is mandated to conduct high-impact health research to improve the quality of life of the Rakyat. The health research conducted by the NIH is in line with the Health Research Priority Areas for each five-yearly Malaysia Plans.

Under this agreement, the parties will explore joint training in the field of medical research, exchange research materials, and partake in scientific data presentation and publication. Additionally, the agreement will enable the exchange of experts and personnel, including postgraduate research and students on adjunct appointments, short- and long-term research attachments, co-supervision of students conducting research and internships, as well as other areas of cooperation to be mutually decided.

To recap, MGRC-T specialises in genomics and biopharmaceutical services with proprietary know-how and intellectual property related to the research, development, and processing of genetic screening tests, as well as the manufacturing of cell therapies, including immunotherapy for various types of cancer.

OLYMPUS DIGITAL CAMERA

“The cooperation agreement enables us to explore ways that we can work together with NIH to improve the quality of our genomics and biopharmaceutical services that can contribute to improving the health of the Rakyat. We consider this collaboration a good step in encouraging and promoting research in genomics and biopharmaceuticals that will be mutually beneficial,” Dato’ Alvin Joseph Nesakumar (photo), Executive Director of Malaysian Genomics remarked.

“We welcome this agreement as we are keen to work with specialists such as Malaysian Genomics to exchange knowledge in various fields of medical research. We believe that by working and pooling our resources together, we can bridge the gaps in expertise and experience,” Dr S Asmaliza Ismail, Manager of the NIH said.

Previous articleMDEC Kicks Off Malaysia Digital Week 2022 To Bolster Malaysia As Region’s Digital Investment Hub
Next articleLoan Applications Increased To RM53.4 Billion In August; MIDF

LEAVE A REPLY

Please enter your comment!
Please enter your name here